Shares of Ânima Educação (ANIM3) slid sharply on Tuesday even as Brazil's Ibovespa climbed, after the company's medical-education arm struck a sweeping 20-year branding and consulting deal with Hospital Albert Einstein that investors quickly judged as too expensive. At one point, ANIM3 fell as much as 8.66% before recovering slightly to around BRL 5.37 , and by late morning the stock was still down roughly 5%. The selloff is entirely company-specific, driven by concerns over how Ânima will pay for an agreement whose total cost may dwarf the upfront headline number.
R$150 Million Is Just the Entry Fee — the Real Bill Runs Much Higher. Ânima's Inspirali unit will pay Einstein R$75 million at signing and another R$75 million one year later, adjusted for inflation. On top of that, Einstein gets a 6% commission on net revenue from every new medical-school class enrolled after the deal closes, paid quarterly.
Additional performance payments start at up to R$10.4 million in 2027 and scale to R$34.1 million by 2036.
BTG Pactual estimates the net present value of all payments could exceed R$600 million — a large sum for a company whose Inspirali division generated roughly R$1.5 billion in net revenue last year.
The Balance Sheet Takes an Immediate Hit. The initial R$75 million cash outlay pushes Ânima's debt-to-earnings ratio (a measure of how much it owes relative to what it earns) from 2.41× to 2.47× on a pro-forma basis — a move analysts flag as risky in Brazil's high-interest-rate environment.
Tuition Hikes Need to Cover the Cost, and That's Uncertain. XP Investimentos calculates the average tuition across Inspirali's 15 schools would need to rise roughly 10% starting in 2027 just to make the deal break even on a present-value basis.
The financial case "remains dependent on execution," with the first real evidence arriving in Q1 2027 when enrollment under the Einstein brand begins.
Wall Street Sees the Logic but Not the Math. Analysts broadly view the partnership favorably on strategic grounds, yet "the costs of the operation prompted caution."
BTG called it "a potentially aggressive capital-allocation decision" and maintained a neutral rating.
Inspirali accounts for **38% of Ânima's total revenue , so the stakes are high: if the Einstein name fills empty seats and justifies premium pricing, the deal pays off. If not, Ânima has locked itself into decades of payments with no easy exit.